Trial reportSchizophrenia research2014
The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: a double-blind, randomized, placebo-controlled trial.
Trial report in Schizophrenia research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02069925 (STEP-ED), which is not on this map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Efficacy and Acceptability of Licensed and Off-Label Pharmacological Interventions for Insomnia in Patients With Severe Mental Illness: A Systematic Review and Meta-Analysis of Randomised Trials.Acta psychiatrica Scandinavica · 2025Pooled it
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials.Sleep medicine reviews · 2021Pooled it
- The role of sleep dysfunction in the occurrence of delusions and hallucinations: A systematic review.Clinical psychology review · 2015Pooled it
- Efficacy of cognitive behavioural therapy for sleep improvement in patients with persistent delusions and hallucinations (BEST): a prospective, assessor-blind, randomised controlled pilot trial.The lancet. Psychiatry · 2015Trial
- Comparison of objective sleep variables in schizophrenia with comorbid insomnia treated with dual orexin receptor antagonists versus benzodiazepine receptor agonists.PCN reports : psychiatry and clinical neurosciences · 2026Article
- Insomnia Symptoms and Psychopathology in Individuals at Clinical High Risk for Psychosis.Early intervention in psychiatry · 2026Article
- Association between pharmacological guideline adherence and actigraphy-measured sleep variables in long-term hospitalized patients with schizophrenia.PCN reports : psychiatry and clinical neurosciences · 2025Article
- Guideline for pharmacological treatment of schizophrenia 2022.Neuropsychopharmacology reports · 2025Article
- Sleep Problems, Suicidal Ideation, and Psychopathology in First-Episode Psychosis.Schizophrenia bulletin · 2024Article
- Effects of new hypnotic drugs on cognition: A systematic review and network meta-analysis.Sleep medicine: X · 2023Review
- Orexin dual receptor antagonists, zolpidem, zopiclone, eszopiclone, and cognitive research: A comprehensive dose-response meta-analysis.Frontiers in human neuroscience · 2022Review
- Prevalence of Circadian Rhythm Sleep-Wake Disorder in Outpatients with Schizophrenia and Its Association with Psychopathological Characteristics and Psychosocial Functioning.Journal of clinical medicine · 2021Article
- The Engram's Dark Horse: How Interneurons Regulate State-Dependent Memory Processing and Plasticity.Frontiers in neural circuits · 2021Review
- Targeting sleep oscillations to improve memory in schizophrenia.Schizophrenia research · 2020Review
- Neuromodulation of sleep rhythms in schizophrenia: Towards the rational design of non-invasive brain stimulation.Schizophrenia research · 2020Review
- Alterations in sleep, sleep spindle, and EEG power in mGluR5 knockout mice.Journal of neurophysiology · 2020Article
- Evidence for an association of serum melatonin concentrations with recognition and circadian preferences in patients with schizophrenia.Metabolic brain disease · 2019Article
- Abnormal Sleep Spindles, Memory Consolidation, and Schizophrenia.Annual review of clinical psychology · 2019Review
- Article
- Sleep Disturbances and Inflammatory Biomarkers in Schizophrenia: Focus on Sex Differences.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundInsomnia is frequent in schizophrenia and may contribute to cognitive impairment as well as overuse of weight inducing sedative antipsychotics. We investigated the effects of eszopiclone on sleep and cognition for patients with schizophrenia-related insomnia in a double-blind placebo controlled study, followed by a two-week, single-blind placebo phase.
methodsThirty-nine clinically stable outpatients with schizophrenia or schizoaffective disorder and insomnia were randomized to either 3mg eszopiclone (n=20) or placebo (n=19). Primary outcome measure was change in Insomnia Severity Index (ISI) over 8 weeks. Secondary outcome measure was change in MATRICS Consensus Cognitive Battery (MATRICS). Sleep diaries, psychiatric symptoms, and quality of life were also monitored.
resultsISI significantly improved more in eszopiclone (mean=-10.7, 95% CI=-13.2; -8.2) than in placebo (mean=-6.9, 95% CI=-9.5; -4.3) with a between-group difference of -3.8 (95% CI=-7.5; -0.2). MATRICS score change did not differ between groups. On further analysis there was a significant improvement in the working memory test, letter-number span component of MATRICS (mean=9.8±9.2, z=-2.00, p=0.045) only for subjects with schizophrenia on eszopiclone. There were improvements in sleep diary items in both groups with no between-group differences. Psychiatric symptoms remained stable. Discontinuation rates were similar. Sleep remained improved during single-blind placebo phase after eszopiclone was stopped, but the working memory improvement in patients with schizophrenia was not durable.
conclusionsEszopiclone stands as a safe and effective alternative for the treatment of insomnia in patients with schizophrenia. Its effects on cognition require further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.